Alzamend Neuro, Inc. (ALZN)
1.13
+0.01
(+0.89%)
USD |
NASDAQ |
Oct 23, 16:00
1.09
-0.04
(-3.54%)
Pre-Market: 09:14
Alzamend Neuro Net Income (Quarterly) : -3.027M for July 31, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | -3.027M |
| April 30, 2026 | -2.870M |
| January 31, 2026 | -2.199M |
| October 31, 2025 | -1.001M |
| July 31, 2025 | -2.703M |
| April 30, 2025 | -1.139M |
| January 31, 2025 | -1.039M |
| October 31, 2024 | -1.362M |
| July 31, 2024 | -0.9744M |
| April 30, 2024 | -0.8515M |
| January 31, 2024 | -2.662M |
| October 31, 2023 | -2.906M |
| Date | Value |
|---|---|
| July 31, 2023 | -3.528M |
| April 30, 2023 | -3.306M |
| January 31, 2023 | -5.426M |
| October 31, 2022 | -3.11M |
| July 31, 2022 | -3.037M |
| April 30, 2022 | -3.869M |
| January 31, 2022 | -2.573M |
| October 31, 2021 | -3.600M |
| July 31, 2021 | -2.320M |
| January 31, 2021 | -1.119M |
| October 31, 2020 | -1.354M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.027M |
| EPS Diluted (Quarterly) | -0.6759 |
| Enterprise Value | -2.138M |
| Earnings Yield | -202.5% |
| Normalized Earnings Yield | -202.48 |